Sherman Law
A5102920454- BRCA gene mutations in cancer
- Genetics, Bioinformatics, and Biomedical Research
- Nutrition, Genetics, and Disease
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Ethics in Clinical Research
- Health Systems, Economic Evaluations, Quality of Life
- Childhood Cancer Survivors' Quality of Life
- Lipoproteins and Cardiovascular Health
- Family Support in Illness
- Pharmaceutical Economics and Policy
- Health Sciences Research and Education
Color (United States)
2020-2023
Requiring personalized genetic counseling may introduce barriers to cancer risk assessment, but it is unknown whether omitting could increase distress.
Abstract Up to 10% of patients with pancreatic ductal adenocarcinoma (PDAC) carry underlying germline pathogenic variants in cancer susceptibility genes. The GENetic Education Risk Assessment and TEsting (GENERATE) study aimed evaluate novel methods genetic education testing relatives PDAC. Eligible individuals had a family history PDAC relative variant APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, or TP53 Participants were recruited at six academic centers...
1506 Background: Hereditary breast and ovarian cancer (HBOC) is preventable when genetic risk identified. We aimed to test whether pre and/or post-test counseling needed optimally deliver online accessible testing. Methods: MAGENTA (Making GENetic Testing Accessible) a four-arm non-inferiority trial evaluating electronic education results delivery alone or combined with pre-test only, only telephone compared mandatory pre- (control arm) in women at of HBOC (NCT02993068). Regardless assigned...
<div>Abstract<p>Up to 10% of patients with pancreatic ductal adenocarcinoma (PDAC) carry underlying germline pathogenic variants in cancer susceptibility genes. The GENetic Education Risk Assessment and TEsting (GENERATE) study aimed evaluate novel methods genetic education testing relatives PDAC. Eligible individuals had a family history PDAC relative variant <i>APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11</i>, or...
<p>Educational Content on the Color Genomics Website</p>
<p>Table of Demographic and Socioeconomic characteristics</p>
<p>Educational Content on the Color Genomics Website</p>
<div>Abstract<p>Up to 10% of patients with pancreatic ductal adenocarcinoma (PDAC) carry underlying germline pathogenic variants in cancer susceptibility genes. The GENetic Education Risk Assessment and TEsting (GENERATE) study aimed evaluate novel methods genetic education testing relatives PDAC. Eligible individuals had a family history PDAC relative variant <i>APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11</i>, or...
<p>Socioeconomic background questionnaire</p>
<p>Socioeconomic background questionnaire</p>
<p>Storyboard for Arm 1</p>
<p>Storyboard for Arm 1</p>
<p>Table of Demographic and Socioeconomic characteristics</p>
Abstract Background: Roughly 7–10% of patients with pancreatic ductal adenocarcinoma (PDAC) have a deleterious germline variant. Although identification variants in family members has implications for cancer surveillance and can lead to early detection interception PDAC, as well other cancers, cascade genetic testing rates are low. The GENetic Education, Risk Assessment TEsting (GENERATE) study evaluates novel methods providing education individuals at risk hereditary PDAC. Methods: Eligible...